

20200311

Release Notes: Version 20200311



About this release

This release (**version 20200311**) provides the latest updates to the Canadian Clinical Drug Data Set in English and French. A separate InfoScribe location for the French supporting documents, including the French Release Notes, can be found [here](#).

There is no change to the Editorial Guidelines and the Technical Specification in this release.

The Canadian Clinical Drug Data Set is available for browsing and download via the [Infoway Terminology Gateway](#).

Supporting general information can be found on Infoway [Canadian Clinical Drug Data Set InfoCentral](#) page.

General Notes

The following files are available as full release files within this version:

- Manufactured Product,
- Non-proprietary Therapeutic Product,
- Therapeutic Moiety,
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in English (MP-NTP-TM Relationship),
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in French (Relation PM-PTC-FT),
- Special Groupings,
- Coded Attribute, and
- Device Non-proprietary Therapeutic Product.

The "Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include "Inactive" content.

NOTE: The "Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.

This release reflects additions and changes that have occurred in DPD since the last CCDD release.

NTP

There is one new deprecated NTP concept with this release. The concept is no longer in use since the dosage form of the corresponding MP changed in DPD.

ntp_code	ntp_formal_name	ntp_fr_description	Type of change
9003416	cefuroxime (cefuroxime axetil) 125 mg per 5 mL powder for oral solution	céfuroxime (céfuroxime axétile) 125 mg par 5 mL poudre pour solution orale	Concept deprecated

MP

mp_code March Release	mp_formal_name March Release	mp_fr_description March Release	mp_formal_name February Release	French mp_formal_name February Release
02212307	CEFTIN (cefuroxime (cefuroxime axetil) 125 mg per 5 mL oral suspension) GLAXOSMITHKLINE INC	CEFTIN (céfuroxime (céfuroxime axétile) 125 mg par 5 mL suspension orale) GLAXOSMITHKLINE INC	CEFTIN - PWS 125MG/5ML (cefuroxime (cefuroxime axetil) 125 mg per 5 mL powder for oral solution) GLAXOSMITHKLINE INC	CEFTIN - PWS 125MG/5ML (céfuroxime (céfuroxime axétile) 125 mg par 5 mL poudre pour solution orale) GLAXOSMITHKLINE INC

Questions, Concerns, Changes

Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at clinicaldrug@infoway-inforoute.ca